LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Core Viewpoint - LENZ Therapeutics has launched VIZZ, the first FDA-approved aceclidine-based eye drop for treating presbyopia, which affects approximately 128 million adults in the U.S. The product is expected to be commercially available by mid-Q4 2025 [1][7]. Product Overview - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to improve near vision for up to 10 hours and is administered as a once-daily eye drop [3][4]. - The mechanism of action involves a predominantly pupil-selective miotic effect, contracting the iris sphincter muscle to create a pinhole effect that enhances depth of focus without causing a myopic shift [1][4]. Clinical Efficacy - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes of application, with effects lasting up to 10 hours [1][4]. Market Potential - Presbyopia is a common age-related condition impacting nearly all individuals over 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [2][5]. - The global market for presbyopia treatments is significant, with an estimated 1.8 billion people affected worldwide [7]. Company Strategy - LENZ Therapeutics is focused on commercializing VIZZ in the U.S. and establishing international licensing partnerships to expand global access [7].